Immunocytokines are a promising immunotherapeutic approach against glioblastoma
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Immunocytokines display promising antitumor activity in orthotopic mouse models of glioma and patients with glioblastoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Specific antibodies (such as L19) against fibronectin to improve tumor response in the clinical trials of patients with glioblastoma by localizing interleukin 2 (IL‐2) or interleukin 12 (IL‐12) in the tumor, leading to increased infiltration of cytotoxic T cells [81, 82, 83].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [81]
Citations
Cites
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“This might be the consequence of glioma cell–intrinsic factors, such as cell-to-cell heterogeneity (5) and the presence of too few immunogenic neoepitopes (6), as well as high levels of immunosuppressive cytokines (7) and immunosuppressive myeloid (8) and lymphoid (9) cell populations, which result in a strong immunos…”
BackgroundAn Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
Neftel, C., Laffy, J., Filbin, M. G., Hara, T., Shore, M. E., Rahme, G. J., Richman, A. R., Silverbush, D., Shaw, M. L., Hebert, C. M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.024 · Cited by 2,873
Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,585
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Bähr, O., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1024 · Cited by 1,501
Self-citationWeller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,134
Self-citationWeller, M., van den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., Henriksson, R., Rhun, E. L., Balana, C., Chinot, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,088
Self-citationThe making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Self-citationChang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
Cited by
Items 101–136 of 136
Next-generation immunotherapy biologics for glioblastoma
Schonfeld, E., Sjoholm, A., Ha, J. P. Y., Liu, J., Nageeb, G., Annagiri, S., Kim, L. H., Choi, J. H., & Lim, M. K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1775093 · Cited by 4
Karavolias, I., Karampinos, K. I., Kani, E.-R., Drougkas, K., Karampinou, V. K., Karavolia, D. M., Koumprentziotis, I., Ploumaki, I., Triantafyllou, E., Lykoudis, P. M., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14397-1 · Cited by 3
Immunocytokines turn up the heat in glioblastoma
Villanueva, M. T. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00188-9 · Cited by 3
Basic premises: searching for new targets and strategies in diffuse gliomas
Sansone, G., Vivori, N., Vivori, C., Stefano, A. L. D., & Pïcca, A. (2022) · Clinical and Translational Imaging · doi:10.1007/s40336-022-00507-7 · Cited by 3
Imaging–guided optimization of biodistribution and antitumor efficacy of L19-based immunocytokines
Virgilio, T., Chahine, K., Carreras, J. G., Pulfer, A., Pizzichetti, C., Latino, I., Romero, D. M., Capucetti, A., Renner, L. L., Neri, D., et al. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102698 · Cited by 2
Self-citationGenerating Shigella that internalize into glioblastoma cells
Shipley, A., Frampton, G. A., Davies, B. W., & Umlauf, B. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1229747 · Cited by 2
A novel ARHGAP family gene signature for survival prediction in glioma patients
Huang, J., Wang, G., Zhang, J., Liu, Y., Shen, Y., Chen, G., Ji, W., & Shao, J. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18555 · Cited by 2
He, D., Qin, Z., Liu, Z., Ji, X., Gao, J., Guo, H., Yang, F., Fan, H., Wei, Y., Wang, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.816760 · Cited by 2
Gong, Y., Ke, Y., Yu, Z., Pan, J., Zhou, X., Jiang, Y., Zhou, M., Zeng, H., Geng, X., & Hu, G. (2023) · Aging · doi:10.18632/aging.204962 · Cited by 1
Breaking the Immune Sanctuary: Targeting Metastatic Niches
Ravishankar, A., Ramamoorthi, G., Weiß, T., Rhun, É. L., Czerniecki, B. J., & Sundar, R. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517520 · Cited by 1
Lipinski, B., Unmuth, L., Tran, T. H. H., Harwood, J., Arras, P., Becker, S., Harwardt, J., Guarnera, E., Helming, L., Zaynagetdinov, R., et al. (2026) · mAbs · doi:10.1080/19420862.2026.2726042 · Cited by 2
Molecular and Macroscopic Therapeutic Systems for Cytokine‐Based Cancer Immunotherapy
Jin, S. M., Lee, S. N., Yoo, Y. J., & Lim, Y. T. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100026 · Cited by 2
ESMO 2022: spotlight on new emerging treatment options in central nervous system tumors
Mair, M. J., & Berghoff, A. S. (2023) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-023-00879-0 · Cited by 1
Sequential Delivery of Aptamer and STING Agonist Shuttled by Graphene Oxide
Zhang, Y., Teng, H., Xie, K., Xia, R., Chen, Z., & Zhou, Y. (2023) · Advances in Computer and Engineering Technology Research · doi:10.61935/acetr.1.1.2023.p111 · Cited by 1
Physiological markers for immunotherapeutics: a review
Chowdhury, D., Das, A., Mishra, M., Khutere, T., & Bodakhe, S. H. (2024) · Journal of Chemotherapy · doi:10.1080/1120009x.2024.2443701 · Cited by 1
Opportunities to Modulate Tumor Ecosystem Toward Successful Glioblastoma Immunotherapy
Takahashi, M., Mukhamejanova, D., Jasewicz, H., Acharya, N., Moon, J. J., & Hara, T. (2025) · Cancer Science · doi:10.1111/cas.70052 · Cited by 1
Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy
Batich, K. A., Sampson, J. H., Khasraw, M., Friedman, H. S., & Ashley, D. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00018-x
Dent, M. (2021) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3789
Wang, D., Jiang, Y., Wang, T., Wang, Z., & Zou, F. (2022) · Figshare · doi:10.6084/m9.figshare.19759733
Wang, D., Jiang, Y., Wang, T., Wang, Z., & Zou, F. (2022) · Figshare · doi:10.6084/m9.figshare.19759739
Sex-specific functional effect of IL-12 gene polymorphisms in brain tumours
Valkanov, S., Grigorov, B., Grigorova, A., Petrov, B., Yusuf, R., & Miteva, L. D. (2024) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2024.2337698
Immuntherapie gegen Gliome - wie ist der Status quo?
Sahm, K., & Weiß, T. (2025) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-025-0922-0
Pfister, S. K., Seehusen, F., Prisco, F., Rotta, G., Elsayed, A., Gilardoni, E., Thorhallsdottir, G., Pellegrino, C. E., Manz, M. G., Puca, E., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0340
Self-citationHindrance in immunotherapy resistant glioblastoma
Bhushan, R., Abubakar, M., Chavan, P. R., Pandey, R., Jamadade, M. S., Murti, K., & Kumar, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33910-3.00005-4
Variability in natural invasion of tumor cells patterns in human glioblastoma
Kumari, D., Chaudhary, P., Janmeda, P., & Kumar, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33910-3.00003-0
Wang, D., Jiang, Y., Wang, T., Wang, Z., & Zou, F. (2022) · Figshare · doi:10.6084/m9.figshare.19759736
Wang, D., Jiang, Y., Wang, T., Wang, Z., & Zou, F. (2022) · Figshare · doi:10.6084/m9.figshare.19759745
Wang, D., Jiang, Y., Wang, T., Wang, Z., & Zou, F. (2022) · Figshare · doi:10.6084/m9.figshare.19759742
Extracellular vesicles as liquid biopsy tools for personalized therapeutic goals in glioblastoma
Menaceur, C., Unnikrishnan, K., Ita, M., Lassen, U., Belting, M., Korshoej, A. R., Bjarkam, C. R., & Chandran, V. I. (2026) · Brain · doi:10.1093/brain/awag003 · Cited by 1
Preclinical testing of a novel therapeutic approach to counteract Glioblastoma
Mori, E. (2025) · Scuola Normale Superiore di Pisa · doi:10.25429/mori-elisabetta_phd2025-11-11
Research Progress of Targeted Therapy Strategies in Tumor Microenvironment
彭朝胜 (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161141
Virgilio, T., Chahine, K., Bansal, H., Pizzichetti, C., Renner, L. L., Capucetti, A., Bilato, G., Latino, I., Morone, D., Pulfer, A., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03678-7
Self-citationWu, Y., Teng, Y., L, Y., Ma, J., Shen, B., & Zhang, Y. (2026) · Acupuncture & Electro-Therapeutics Research · doi:10.1177/03601293261450678
Su, Y., Lu, Y., Yu, J., Jin, C., Chen, Y., Lu, W., & Ding, J. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18081028
Targeting extracellular matrix mechanobiology to suppress solid tumor progression
Boone, K., Kondapaneni, R. V., Libring, S., & Reinhart‐King, C. A. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218856
Killing with a purpose: harnessing immunological cell death in brain tumors
Young, R. G., Edgerton, A. O., Clouser, K. A., Kutzler, M. A., Haddad, E. K., & Reginato, M. J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1973683
Metadata
- Authors
- Weiss, T., Puca, E., Silginer, M., Hemmerle, T., Pazahr, S., Bink, A., Weller, M., Neri, D., & Roth, P.
- Affiliations
- University of Zurich (CH)
- ETH Zurich (CH)
- Philochem (Switzerland) (CH)
- Corresponding author
- Weiss, Tobias
- Puca, Emanuele
- Neri, Dario
- Roth, Patrick
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2020-10-07
- Volume
- 12
- Issue
- 564
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3092445835
- Cited by
- 133
- References
- 54
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 27 · 2023: 24 · 2022: 24 · 2021: 21 · 2020: 1
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- European Research Council (670603)
- Swiss National Science Foundation (SNF 310030_170027, 323630_164218, 310030_182003/1)
- Oncosuisse (KFS-4544-08-2018-R)
- Forschungskredit University of Zurich (FK-18-054)
- Swiss Cancer Research Foundation (MD-PhD-3558-06-2015)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- immunocytokines, glioblastoma, tumor-infiltrating lymphocytes, tumor microenvironment, inflammatory cytokines, adaptive immunity, tumor necrosis, CD4+ T cells, CD8+ T cells, tumor perfusion, immunotherapy
- MeSH terms
- Animals, Glioblastoma, Humans, Immunotherapy, Interleukin-2, Cytokines, CD8-Positive T-Lymphocytes, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.